Digital Event Horizon
In a groundbreaking development, Multiply Labs has successfully scaled up its robotic systems to produce gene-modified cell therapies at an unprecedented scale. This innovative approach has reduced production costs by over 70% while significantly increasing throughput, making these life-saving treatments more accessible to millions of patients worldwide. Learn how robotics is revolutionizing cell therapy manufacturing and ushering in a new era of precision and efficiency.
Multiply Labs has scaled up its robotic systems to produce gene-modified cell therapies at an unprecedented scale. The company's innovative approach reduces production costs by over 70% and significantly increases throughput. Robots execute each task with precision, consistency, and traceability around the clock, reducing human error and increasing efficiency. Multiply Labs' unique simulation-based approach mitigates knowledge loss due to staff turnover, ensuring continuity and efficiency in operations.
In a groundbreaking development, Multiply Labs, a pioneering startup in the field of robotics-driven biomanufacturing, has successfully scaled up its robotic systems to produce gene-modified cell therapies at an unprecedented scale. This innovative approach has not only reduced production costs by over 70% but also significantly increased throughput, making these life-saving treatments more accessible to millions of patients worldwide.
The journey began when Fred Parietti, co-founder and CEO of Multiply Labs, met Alice Melocchi, a cell therapy researcher, who revealed to him the laborious and tedious nature of lab work in biomanufacturing. This encounter sparked an idea – to introduce robots to perform the tedious, precision, and hygienic work better, faster, and cheaper. Parietti's vision was to bring about a new era in biosciences, leveraging robotics to usher in precision gains, reduced contamination, and advanced manufacturing with physical AI.
Through its cutting-edge robotic systems, Multiply Labs is automating cell therapy manufacturing for leading companies, including Kyverna Therapeutics and Legend Biotech. These systems utilize end-to-end automation, producing gene-modified cell therapies at scale. By leveraging NVIDIA's Omniverse libraries for developing digital twins of lab environments and the NVIDIA Isaac Sim robotics simulation framework for training robots on bespoke skills required to develop these treatments, Multiply Labs has created a robust and scalable solution.
Cell therapies have shown tremendous promise in treating various diseases, including cancers, genetic disorders, autoimmune diseases, and neurological conditions. However, their complexity and cost have historically limited access. The manufacturing process involves thousands of precise, sterile steps – moving liquids between vessels, stirring bags and syringes without introducing bubbles, maintaining exact temperatures – all within tight time constraints. Human error, even in a single step, can compromise the entire process.
Robots, on the other hand, execute each task with precision, consistency, and traceability around the clock. They don't breathe, stop, or deviate, ensuring that every process is carried out without human intervention. By harnessing humanoid robots developed using NVIDIA Isaac GR00T N foundation models, Multiply Labs has transformed messy human demonstrations into clean control policies, allowing robots to learn fast and deploy faster.
The result of this innovative approach is a fully automated manufacturing floor where humans watch from behind the glass, and humanoids – powered by Isaac GR00T – keep the process flowing, clean, and contamination-free. This not only reduces costs but also increases throughput, enabling up to 100 times more therapies to be produced per square foot of facility space.
Furthermore, Multiply Labs has developed a unique approach to mitigate knowledge loss due to staff turnover, which can cripple production. By training robots on the exact video example of the best scientist and proving that they are statistically equivalent, the company ensures continuity and efficiency in their operations. This simulation-based approach utilizes digital twins from NVIDIA Omniverse to run thousands of virtual iterations, identifying and resolving nearly all mechanical bugs before real-world deployment.
In a bold statement, Fred Parietti, co-founder and CEO of Multiply Labs, emphasized that "We want to enable the shift of the industry from niche to scale – 100 times more therapies at 70% less cost – so life-saving treatments aren't just for the few, but for the millions." This vision is a testament to the potential of robotics-driven biomanufacturing and its capacity to revolutionize the cell therapy industry.
As the industry continues to evolve, Multiply Labs' innovative approach serves as a beacon of hope for millions of patients worldwide. By harnessing the power of robots, artificial intelligence, and physical AI, this startup is ushering in a new era of precision and efficiency, making life-saving treatments more accessible to those who need them most.
Related Information:
https://www.digitaleventhorizon.com/articles/A-New-Era-of-Precision-and-Efficiency-How-Robotics-is-Revolutionizing-Cell-Therapy-Manufacturing-deh.shtml
https://blogs.nvidia.com/blog/multiply-labs-isaac-omniverse/
Published: Sat Jan 17 04:36:29 2026 by llama3.2 3B Q4_K_M
